Raltitrexed–Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients

Porta, Camillo; Zimatore, Matteo; Bonomi, Lucia; Imarisio, Ilaria; Paglino, Chiara; Sartore-Bianchi, Andrea; Mutti, Luciano

doi:10.1016/j.lungcan.2004.11.015

Cited by 48 publications

(24 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These data need confirmation in a randomised study. The available data on this topic are rare (six phase II studies [65][66][67][68][69][70]) and do not allow proposal of a particular chemotherapy schedule. It is recommended to include patients in good general condition in clinical studies, with this approach being ethically acceptable.…”

Section: Chemotherapy Of Mpmmentioning

confidence: 99%

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

Scherpereel¹,

Astoul²,

Baas³

et al. 2009

Eur Respir J

548

504

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare tumour but with increasing incidence and a poor prognosis. In 2008, the European Respiratory Society/European Society of Thoracic Surgeons Task Force brought together experts to propose practical and up-to-dated guidelines on the management of MPM.To obtain an earlier and reliable diagnosis of MPM, the experts recommend performing thoracoscopy, except in cases of pre-operative contraindication or pleural symphysis. The standard staining procedures are insufficient in ,10% of cases. Therefore, we propose using specific immunohistochemistry markers on pleural biopsies. In the absence of a uniform, robust and validated staging system, we advice use of the most recent TNM based classification, and propose a three step pre-treatment assessment. Patient's performance status and histological subtype are currently the only prognostic factors of clinical importance in the management of MPM. Other potential parameters should be recorded at baseline and reported in clinical trials. MPM exhibits a high resistance to chemotherapy and only a few patients are candidates for radical surgery. New therapies and strategies have been reviewed.Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach should be included in a prospective trial at a specialised centre.

show abstract

Section: Chemotherapy Of Mpmmentioning

confidence: 99%

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

Scherpereel¹,

Astoul²,

Baas³

et al. 2009

Eur Respir J

548

504

View full text Add to dashboard Cite

show abstract

“…However, as PSC was not randomized, it is not possible to know whether the reduced risk of death was associated with PSC or whether patients who had prolonged survival tended to receive more PSC. In addition, some phase II trials on second-line chemotherapy have recently been published [141,142,143], with sometimes conflicting results [144, 145] (table 2). Thus, no standard treatment can be defined after failure of first-line chemotherapy.…”

Section: Malignant Pleural Mesotheliomamentioning

confidence: 99%

Mesothelioma and Asbestos-Related Pleural Diseases

Greillier¹,

Astoul²

2008

Respiration

View full text Add to dashboard Cite

At present, the use of asbestos is not regulated at a worldwide scale. Moreover, there is a latency period between asbestos exposure and the manifestations of asbestos-related diseases. Consequently, pulmonologists are still dealing with consequences of asbestos exposure, which mainly occur at the pleural surface. The aim of this review is to provide an overview of asbestos-related pleural diseases. We summarized the most relevant data for the diagnosis and the management of benign asbestos pleural effusions, pleural plaques, diffuse pleural thickening and rounded atelectasis. Special attention is dedicated to malignant pleural mesothelioma, given the challenging issues of this disease, the recent advances in its management and the dynamism of research in this area.

show abstract

“…The combination of cisplatingemcitabine (48), irinotecan-cisplatin-mitomycin (49), and oxaliplatin-raltitrexed (50,51), have also been evaluated as second-line approaches. Additionally, in the phase II trial by Giaccone et al, the platinum-complex ZD0473 showed no benefit as second-line strategy (52).…”

Section: Second-line Treatment With Single-agent Ctmentioning

confidence: 99%

Chemotherapy treatment in malignant pleural mesothelioma: a difficult history

et al. 2018

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare neoplasm that typically arises from mesothelial surfaces of the pleural cavity. Despite treatment improvements, it carries a dismal prognosis. The majority of patients either have unresectable disease or are not candidates for surgery due to medical comorbidities or old age. For such patients, chemotherapy (CT) represents the gold-standard treatment. To date, combination CT with cisplatin plus pemetrexed represents the most widely used regimen in first-line setting for patients with unresectable MPM. Other first-line options are currently available, including the use of raltitrexed instead of pemetrexed combined with platinum. In this review, we discuss the role of CT in MPM mainly focusing on the results of the trials conducted in first-line setting.

show abstract

Raltitrexed–Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients

Cited by 48 publications

References 33 publications

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

Mesothelioma and Asbestos-Related Pleural Diseases

Chemotherapy treatment in malignant pleural mesothelioma: a difficult history

Contact Info

Product

Resources

About